EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas.

@article{Chen2012EGFRMH,
  title={EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas.},
  author={Zhi-yong Chen and Wen-Zhao Zhong and Xuchao Zhang and Jian Su and Xue-ning Yang and Zhi-Hong Chen and Jinji Yang and Qing Sheng Zhou and Hong-hong Yan and She-juan An and Hua-jun Chen and Ben-yuan Jiang and Tony Shu Kam Mok and Yi-Long Wu},
  journal={The oncologist},
  year={2012},
  volume={17 7},
  pages={978-85}
}
BACKGROUND Non-small cell lung cancer patients with epidermal growth factor receptor (EGFR) mutations have mixed responses to tyrosine kinase inhibitors (TKIs). Intertumor heterogeneity in EGFR mutations is one potential explanation for this phenomenon. METHODS We performed direct sequencing to identify EGFR mutations in 180 pairs of lung adenocarcinoma samples (from 3,071 patients). The high-resolution melting method was used in discordant cases to confirm EGFR mutation status. Matching… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 16 times over the past 90 days. VIEW TWEETS
57 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 57 extracted citations

Similar Papers

Loading similar papers…